Efficacy and Safety of Modified Hepatic Artery Infusion Chemotherapy (TOMOX-HAIC) in Combination With Sintilimab and Bevacizumab Biosimilar for the First-line Treatment of Advanced Hepatocellular Carcinoma: a Prospective, Single-arm, Phase II Clinical Study
This is a single-center, single-arm, phase II clinical study, to explore the efficacy and safety of modified TOMOX-HAIC combined with sintilimab and bevacizumab biosimilar as first line treatment in patients with advanced hepatocellular carcinoma.
• Be willing and able to provide written informed consent/assent for the trial.
• Males or unpregnant females who age ≥ 18 years, ≤75 years.
• The investigator believes the patient is capable of complying with the study protocol.
• Histologically, cytologically or clinically confirmed advanced hepatocellular carcinoma.
• is not a candidate for radical surgery
• not received previous systemic treatment
• patients must have at least one measurable lesion (RECIST 1.1)
• ECOG PS：0-1, 14 days before enrollment
• Child-Pugh A or Child-Pugh B ≤ 7, 14 days before enrollment